



uniQure to Participate in Multiple Upcoming Industry Conferences in May

May 3, 2021

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 03, 2021 (GLOBE NEWSWIRE) -- [uniQure N.V.](#) (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:

- **7th Annual Truist Securities Life Sciences Summit, May 4 - 5, 2021**
 - Members of uniQure's management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, May 4.
- **American Society of Gene and Cell Therapy (ASGCT) Virtual 2021, May 11 - 14, 2021**
 - uniQure will have a significant presence at ASGCT with five data presentations, of which two are oral presentations including:
 - “*Clinical Outcomes in Patients With and Without Pre-existing Neutralizing Antibodies to the Vector: 6-Month Data from the Phase 3 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec*” on Wednesday, May 12, 6:15 – 6:30 p.m. ET.
 - “*First Proof-of-Concept of miQURE™ Based Gene Targeting in the Liver: Lipid Lowering and Atherosclerosis Suppression by AAV-miQURE™-Mediated ANGPTL3 Targeting*” on Thursday, May 13, 6:30 – 6:45 p.m. ET.
- **2021 RBC Capital Markets Global Healthcare Conference, May 18 - 19, 2021**
 - Members of uniQure's management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, May 18.
 - A fireside chat with [Matt Kapusta](#), chief executive officer, will take place the same day from 9:10 to 9:35 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the [Investors & Newsroom](#) section of the uniQure website.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a [pipeline](#) of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:

Maria E. Cantor

Direct: 339-970-7536

m.cantor@uniQure.com

Chiara Russo

Direct: 617-306-9137

c.russo@uniQure.com

FOR MEDIA:

Tom Malone

Direct: 339-970-7558

t.malone@uniQure.com